HYDROIAM Contraindications

Contraindications:

1. HYDROIAM is contraindicated in patients with a history of severe allergic reactions, and in those with a history of multiple severe allergies.

2. It is contraindicated in patients with a known allergy to streptococcal proteins, as the product may contain trace amounts of these materials.

3. The following conditions prohibit the use of HYDROIAM:

Areas previously injected with permanent fillers or non-hyaluronic acid fillers.

Areas where non-permanent fillers were used within the past 6-12 months.

Areas previously injected with facial fillers where the type of filler is unknown.

4. It is contraindicated in patients with coagulation disorders or those who have undergone treatment with thrombolytic agents or anticoagulants.

5. Active disease at or near the treatment site, such as inflammation, infection, or tumors.

Warnings:

1.  HYDROIAM is intended for injection only into the dermis and/or subcutaneous tissue. This product must not be used for injections into the breast area.

2. HYDROIAM must not be re-sterilized.

3. Never inject into muscle or blood vessels. It is recommended to perform aspiration before injection to confirm.

4. Accidental injection of soft tissue filler into facial blood vessels may cause embolism, vascular occlusion, local ischemia, necrosis, or infarction at the injection site, or impair blood supply in the affected area. Rare but serious adverse events include temporary or permanent vision impairment, blindness, cerebral ischemia, or infarction. If the skin surface turns pale (blanching) or the patient complains of unusual pain or any symptoms related to intravascular injection occur, injection should be stopped immediately, and urgent medical assessment and care must be provided.

5. Do not mix HYDROIAM with other products before injection.

6. This product is for single use only.

7. Do not use if the packaging is damaged.

Precaution:

1. The same routine precautions related to intradermal injections apply; all injection procedures carry a risk of infection, therefore injecting  HYDROIAM  also carries an infection risk. The injection process must strictly adhere to aseptic surgical principles.

2. Use with caution in immunosuppressed patients.

3. Exercise particular caution when treating areas near permanent implants.

4. Special care is needed to avoid puncturing or compressing blood vessels, nerves, and other vulnerable structures. Injection should be slow, and injection pressure minimized to reduce the risk of complications.

5. Patients taking medications that affect platelet function (such as aspirin and non-steroidal anti-inflammatory drugs) may experience increased bruising or bleeding at the injection site.

6. The injection procedure may activate latent or subclinical herpes virus infections.

7. Injection that is too superficial may cause visible lumps and/or bluish discoloration at the treatment site.

8. Noticeable nodules may be difficult to correct; the extent and duration of correction depend on the treatment characteristics, tissue pressure at the implant site, depth of implantation, and injection technique.

9. Patients with unrealistic expectations should not use  HYDROIAM 

10. After treatment with  HYDROIAM , if laser therapy, chemical peeling, or other treatments that can cause dermal activity reactions are performed immediately, there is a theoretical risk of inducing inflammation at the injection site. Similarly, if  HYDROIAM  treatment is given before the skin has fully healed from such therapies, there is also a potential risk. It is recommended to avoid  HYDROIAM  treatment for 2 to 4 weeks before these procedures, and patients who have undergone such treatments should wait until complete skin healing before receiving  HYDROIAM  injections.

11. Patients must be informed that before swelling and redness subside, the injection site should not be exposed to high temperatures (such as sunbathing, steam baths, or excessive sun exposure) or extreme cold, nor should it undergo skin treatments (such as facial massage or masks at the injection site).

12. The safety of HYDROIAM  has not been established in pregnant women, nursing mothers, or children.

13. Patients should be guided to verify product authenticity and retain product tracking information.